Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells

Cancer statistics, 2014

Rebecca L. Siegel, Jiemin Ma, Zhaohui Zou et al. · CA A Cancer Journal for Clinicians · 2014 · 11.6K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

David A. Barbie, Pablo Tamayo, Jesse S. Boehm et al. · Nature · 2009 · 4.2K citations · Full text

Medicine, Cancer Biology, Molecular Biology +13

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

J.M. Ostrem, Ulf Peters, Martin L. Sos et al. · Nature · 2013 · 2.5K citations · Full text

Life Sciences, Molecular Biology, Pharmacology +14

Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

Cun-Yu Wang, James C. Cusack, Rong Liu et al. · Nature Medicine · 1999 · 994 citations

Medicine, Cancer Biology, Oncology +14

Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.

Etienne Meylan, Alison L. Dooley, David M. Feldser et al. · PubMed · 2009 · 520 citations · Full text

Medicine, Molecular Biology, Oncology +16